ES2116298T3 - Nuevo metodo de tratamiento de la depresion. - Google Patents

Nuevo metodo de tratamiento de la depresion.

Info

Publication number
ES2116298T3
ES2116298T3 ES91918381T ES91918381T ES2116298T3 ES 2116298 T3 ES2116298 T3 ES 2116298T3 ES 91918381 T ES91918381 T ES 91918381T ES 91918381 T ES91918381 T ES 91918381T ES 2116298 T3 ES2116298 T3 ES 2116298T3
Authority
ES
Spain
Prior art keywords
new method
depression treatment
depression
treatment
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918381T
Other languages
English (en)
Inventor
Jan David Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2116298T3 publication Critical patent/ES2116298T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO USO DE AMINOACIDOS CICLICOS CONOCIDOS. TALES COMPUESTOS, QUE INCLUYEN GABAPENTINA, SON UTILES PARA EL TRATAMIENTO DE TIPOS DE DEPRESION DE MAYOR Y MENOR IMPORTANCIA.
ES91918381T 1990-10-12 1991-10-02 Nuevo metodo de tratamiento de la depresion. Expired - Lifetime ES2116298T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/596,270 US5025035A (en) 1990-10-12 1990-10-12 Method of treating depression

Publications (1)

Publication Number Publication Date
ES2116298T3 true ES2116298T3 (es) 1998-07-16

Family

ID=24386662

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918381T Expired - Lifetime ES2116298T3 (es) 1990-10-12 1991-10-02 Nuevo metodo de tratamiento de la depresion.

Country Status (11)

Country Link
US (1) US5025035A (es)
EP (1) EP0552240B1 (es)
JP (1) JP3192141B2 (es)
AT (1) ATE164065T1 (es)
CA (1) CA2092416A1 (es)
DE (1) DE69129115T2 (es)
DK (1) DK0552240T3 (es)
ES (1) ES2116298T3 (es)
GR (1) GR3026519T3 (es)
MX (1) MX9101526A (es)
WO (1) WO1992006686A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
HU224720B1 (en) * 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
AU9019198A (en) 1997-08-19 1999-03-08 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
ATE323067T1 (de) * 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
ATE271864T1 (de) 1998-05-15 2004-08-15 Warner Lambert Co Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
TR200102850T2 (tr) * 1999-04-09 2002-03-21 Warner-Lambert Company Depresyonun iyileçtirilmesi i‡in gaba analoglarì ve trisiklik bileçiklerin kombinasyonlarì
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
DE60101476T2 (de) 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. Stabiles gabapentin, das mehr als 20 ppm chlor enthält
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
EP0552240A4 (en) 1993-09-01
EP0552240A1 (en) 1993-07-28
JPH06502148A (ja) 1994-03-10
DE69129115D1 (de) 1998-04-23
EP0552240B1 (en) 1998-03-18
GR3026519T3 (en) 1998-07-31
CA2092416A1 (en) 1992-04-13
DK0552240T3 (da) 1998-11-23
DE69129115T2 (de) 1998-07-16
MX9101526A (es) 1992-06-05
WO1992006686A1 (en) 1992-04-30
US5025035A (en) 1991-06-18
ATE164065T1 (de) 1998-04-15
JP3192141B2 (ja) 2001-07-23

Similar Documents

Publication Publication Date Title
ES2116298T3 (es) Nuevo metodo de tratamiento de la depresion.
DK0429570T3 (da) Osteoinducerende præparater
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
ES2063912T3 (es) Composiciones inmunogenicas frente a peptidos de gastrina.
ATE150319T1 (de) Behandlung von asthma
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
ATE40646T1 (de) Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat.
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
HUP9700598A2 (hu) Eljárás hasnyálmirigy-gyulladás megelőzésére és kezelésére alkalmas gyógyszerkészítmény előállítására
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE58907851D1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ES2139573T3 (es) Procedimiento de preparacion industrial de la 4-cloro-3-sulfamoil-n-(2,3-dihidro-2-metil-1h-indol-1-il)-benzamida.
ES2159287T3 (es) Peptidos hemorreguladores.
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
ATE130304T1 (de) Neue alpha-glukosidaseinhibitoren.
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
ATE82124T1 (de) Anwendung von n-(2-(diaethylamino)aethyl>-2-methoxy-4((1-h-4,5ihydro-2-imidazolyl)amino>-5- chlorobenzamid als anxiolytisches und antipsychotisches mittel.
ATE284706T1 (de) Neue verbesserte formulierung zur behandlung von thromboembolismus
DE69011702D1 (de) Derivate von Aminocarboxylsäure.
ATE68175T1 (de) Verfahren zur herstellung von l,l oder d,d oder racemat n6 benzyloxycarbonyl 2,6 diaminopimelinsaeuremonoamid.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552240

Country of ref document: ES